
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is a leading multinational healthcare company that offers molecular diagnostic tests and services to personalize cancer diagnosis and treatment. With a strong focus on urologic cancers, the company's proprietary genomic, epigenetic, and other molecular technologies provide physicians with actionable information to improve patient outcomes. Despite a recent setback with its Resolve UTI test, the company is poised for long-term growth with a portfolio of top-performing tests recommended under NCCN guidelines. Its recent acquisition of Exosome Diagnostics further strengthens its position in the urology market and presents potential cost-savings to the U.S. healthcare system. With a path to positive free cash flow and a disciplined approach to potential growth opportunities, MDxHealth is well-positioned for success.
Bears say
MDxHealth is facing several challenges that have led to a negative outlook on the stock. These challenges include the discontinuation of its Resolve UTI test due to a CMS matter, a Q1 miss and lowered guidance, and the company's unwillingness to pursue alternative billing strategies. Despite its recent acquisition of the ExoDx test and expected growth from its Oncotype DX prostate cancer test, MDxHealth's fundamentals remain weak, with missed revenue and EBITDA estimates for Q1. Additionally, the company's lack of transparency regarding specific tests and declining tissue volume add to the uncertainty of its future performance.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares